GlassScriptPhysician profile
Tiffany Wesley Ardoin
NPI 1821484080
$996.11
in general payments reported to CMS, 2019-2025
13 companies · $593 in 2025
The $593 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $153 · 2022: $16.30 · 2024: $234 · 2025: $593.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $827.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $826.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $329.50 | 2024-2025 | Wegovy |
| Abbott Laboratories | $206.87 | 2025 | Freestyle Libre 3 |
| Lilly USA, LLC | $159.03 | 2024-2025 | Mounjaro, Jardiance, Zepbound |
| Merck Sharp & Dohme LLC | $152.24 | 2019-2025 | Capvaxive, Gardasil 9 |
| Bayer Healthcare Pharmaceuticals INC. | $23.88 | 2025 | |
| Pfizer INC. | $18.20 | 2025 | |
| Phathom Pharmaceuticals, INC. | $17.60 | 2024 | Voquezna |
| Myovant Sciences INC. | $16.30 | 2022 | |
| Currax Pharmaceuticals LLC | $15.43 | 2025 | Contrave |
| Sumitomo Pharma America, INC. | $15.23 | 2025 | Gemtesa |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $14.85 | 2019 | |
| Idorsia Pharmaceuticals US INC | $13.50 | 2024 | Quviviq |
| Astrazeneca Pharmaceuticals LP | $13.48 | 2025 | Farxiga |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tiffany Ardoin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.